期刊
PHARMACOLOGICAL RESEARCH
卷 179, 期 -, 页码 -出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2022.106232
关键词
Ovarian cancer; Patient derived organoid; PARP inhibitor; Functional test; Resistant mechanism; Combination therapy
资金
- National Key Research and Development of China [2021YFF0502400]
- Innovative research team of high-level local universities in Shanghai [22137006 82073713 82104033, U2106227]
- National Natural Science Foundation of China
This study establishes patient-derived organoids (PDOs) from epithelial ovarian cancer (EOC) and evaluates their sensitivity to poly ADP-ribose polymerase inhibitors (PARPi). The PDOs recapitulate patient clinical response and demonstrate heterogeneity in drug response. The study also reveals potential mechanisms of resistance and identifies combination strategies to reverse resistance.
With the common use of poly ADP-ribose polymerase inhibitors (PARPi) for the man-agement of epithelial ovarian cancer (EOC) across the treatment life cycle, there is a critical need for the development of functional tests, as a complementary to genomic assays, in the study of PARPi sensitivity and resistance. Patient-derived organoids (PDOs) are found feasible for rapid functional testing and predicting drug response. Here, we estab-lished a series of PDOs from EOC and tested the sensitivity of seven cases to various agents including PARPi. PDOs recapitulated patient clinical response to platinum chemotherapy and displayed drug response heteroge-neity to targeted agents including PARPi. Of three PDOs harboring mutational signature of homologous recombination repair (HRR) deficiency, two were PARPi sensitive while one was inherent resistant. Another PDO derived from a patient who relapsed during olaparib maintenance therapy was found acquired resistant to PARPi. Subsequent functional analysis revealed the potential resistant mechanisms related to replication fork protection and HRR functional restoration, and combination strategies targeting the mechanisms could reverse the resis-tance. Our research demonstrated the capacity of EOC PDOs for evaluating the sensitivity to PARPi under different settings, exploring mechanisms of resistance, and identifying effective combined strategies, which has implications for the clinical application of PARPi.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据